Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations

Conditions: Metastatic Hormone-sensitive Prostate Cancer (mHSPC); Deleterious HRR Gene Mutation; BRCA1 Gene Mutation; BRCA2 Gene Mutation; BRIP1 Gene Mutation; CHEK2 Gene Mutation; FANCA Gene Mutation; PALB2 Gene Mutation; RAD51B Gene Mutation; RAD54L Gene Mutation Interventions: Drug: Androgen deprivation therapy (ADT); Drug: Niraparib/Abiraterone Acetate; Drug: Abiraterone acetate; Drug: Prednisone; Drug: Docetaxel Sponsors: Qian Qin; UT Southwestern Comprehensive Cancer Center; Janssen, LP Not yet recruiting

https://clinicaltrials.gov/study/NCT06392841

Source: ClinicalTrials.gov - April 30, 2024 Category: Research Source Type: clinical trials